Kate Sears

Hi I'm Kate, community lead for @OpenMedicineHQ. Open access and free for everyone.

[gilberto lopes @GlopesMd]

1/ November is Lung Cancer Awareness Month.
We cannot make assumptions about our patients' preferences, perspectives and priorities

@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch

[Talha Badar @TalhaBadarMD]

🩸 #ASH26 | #ALL abstracts to watch 👀
My picks from this year’s oral ALL sessions, spanning in vivo T-cell engagement, next-gen CAR-T, T-ALL, salvage after CAR-T, older adults, Ph+ ALL, and MRD-guided therapy.

A thread 🧵👇

#373 | Sentry-CD19
First-in-human in vivo gene-encoded CD19×CD3 T-cell engager in R/R B-cell malignancies.

→ Both B-ALL pts achieved MRD negativity
→ Grade 4 ICANS was a DLT
📅 Sat Dec 12 | 4:00 PM
#374 | SUMM1T
Third-generation CD19 CAR-T naricabgene autoleucel in R/R B-ALL/B-NHL.

→ 19/19 B-ALL achieved CR/CRi
→ 12-mo PFS: 82.1%
📅 Sat Dec 12 | 4:15 PM

#375 | Nanotrident-2
CD19/CD22 tandem CAR-T for B-ALL refractory to prior blinatumomab, inotuzumab or single-target CAR-T.
→ ORR 91.1%
→ IEC-HS: 22.2%

An important strategy for immune-refractory disease.
📅 Sat Dec 12 | 4:30 PM
#378 | SWOG S1905
OBI-3424 in R/R T-ALL.

Important negative study:
→ No CR/CRi at the MTD

Not every “abstract to watch” needs to be positive. Negative trials help define where we go next.
📅 Sat Dec 12 | 5:15 PM

#764 | Salvage after CART19
What happens when pediatric/AYA B-ALL relapses after CD19 CAR-T?
→ Median OS from relapse: 15 mo
→ Inotuzumab and CART22 provided the best salvage outcomes
Highly relevant to post-CAR-T sequencing.

📅 Mon Dec 14 | 10:45 AM
#894 | Older adults with ALL
GMALL registry experience with pediatric-based chemotherapy + stepwise incorporation of immunotherapy.

→ OS improved from 45% → 70% across treatment eras

A compelling look at how immunotherapy is reshaping treatment for older adults.
📅 Mon Dec 14 | 4:00 PM

#998 | Blinatumomab + asciminib
Phase I/II study in newly diagnosed or R/R Ph+ ALL.
→ 17 pts
→ All achieved CR
→ Asciminib 200 mg selected as RP2D
A chemotherapy-light/targeted approach worth following.

📅 Mon Dec 14 | 4:45 PM

#1000 | E1910
Does blinatumomab still matter when highly sensitive NGS says MRD-negative?

→ Benefit seen in both molecular MRD-negative and MRD-positive pts
→ OS HR 0.31 in both groups

Potentially practice-informing data on how we interpret deep MRD negativity.
📅 Mon Dec 14 | 5:15 PM

#1002 | ATRIALL / GRAALL-2014/T
Nelarabine-based consolidation + maintenance in frontline high-risk adult T-ALL.
→ 4-yr DFS 65.1% vs 53.6%
→ Difference not statistically significant
Important final data for defining nelarabine’s role in adult T-ALL.

📅 Mon Dec 14 | 5:45 PM
Lots to follow at #ASH26 in ALL.

What’s on your must-see list?
#ALLsm #Leusm #ASH2026 @oncodaily @OpenMedKate @Larvol

[Michael H. Tomasson, MD @MTomasson]

@OpenMedInsights @OpenMedKate @VincentRK @OpenMedicineHQ @scserendipity1 Well done for our current reality where we discover MGUS incidentally. Should we screen higher risk groups routinely for MGUS?
https://t.co/903Suis0iM

[gilberto lopes @GlopesMd]

The administration is ushering in peptides. Here are my concerns.

@medpagetoday

https://t.co/2BRKhIt7sg

@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch

[Kate Sears @OpenMedKate]

Love #MedTwitter but not the noise? Get practice changing updates from social media.

Subscribe to our weekly newsletter and join your colleagues. Sign up free!

https://t.co/KsxGWQxmCS

[Kate Sears @OpenMedKate]

Hi friends, it's #LungCancer Wednesday! Here are Top Posts of the Week 🧵

1/ @BrendonStilesMD on Medicaid expansion and greater use of surgery in NSCLC:
https://t.co/CSfsTpgU60

[Brendon Stiles @BrendonStilesMD]

Proud to share our new paper in @annalsthorsurg, led by Olga Ostrovetsky.

In >1.5 million patients with NSCLC, Medicaid expansion was associated with earlier-stage diagnosis and greater use of surgery.

Health policy matters for cancer outcomes.

https://t.co/s7B4QO7a8a

[Kate Sears @OpenMedKate]

5/ @StephenVLiu on a talk from @Alfdoc2 on the value of adjuvant therapy following neoadjuvant for resectable NSCLC:
https://t.co/Z8Zu3vqRbk

[Stephen V Liu, MD @StephenVLiu]

Dr. @Alfdoc2 debates the value of adjuvant therapy following neoadjuvant for resectable NSCLC - is there a clear benefit that justifies the excess cost, particularly for those who achieve pCR?

[Open Medicine Insights @OpenMedInsights]

Algorithm video: (<1 min). @VincentRK @OpenMedicineHQ @OpenMedKate @scserendipity1

[Kate Sears @OpenMedKate]

@DanaFarber @DrHBurstein @harvardmed Way to go, Hal! 👏👏👏

[Kate Sears @OpenMedKate]

@Abdallah81MD @Larvol @oncodaily @USMIRCNEWS @US_HMC 👏👏👏

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🎬 My final video from the National ICE-T Congress in Kansas City! Enjoy 😉

What an incredible event! 🙌🔥 A tremendous success, bringing together outstanding experts in cellular therapy!

Thank you, @OpenMedKate @Larvol @oncodaily @USMIRCNEWS @US_HMC

🚀 Next stop: Oklahoma City, January 30, 2027!

See you at the next National ICE-T Congress, chaired by @Taha_CancerDoc!

[Open Medicine Insights @OpenMedInsights]

Algorithm on video @OpenMedicineHQ

[Open Medicine @OpenMedicineHQ]

World Health Organization Surgical Safety Checklist from @amerseburger: https://t.co/Pp3dN7hHYb

[Kate Sears @OpenMedKate]

Love #MedTwitter but not the noise? Get practice changing updates from social media.

Subscribe to our weekly newsletter and join your colleagues. Sign up free!

https://t.co/KsxGWQxmCS

[Kate Sears @OpenMedKate]

Hi friends, it's #BreastCancer Tuesday! Here are Top Posts of the Week 🧵

1/ @PTarantinoMD on IKS014 shows 50% ORR post-T-DXd:
https://t.co/IpWsV4Xief

[Paolo Tarantino @PTarantinoMD]

Switching ADC payload works. Even while keeping the same target.

We previously saw it in DB02. Then in TULIP. And now in ph1 trials of novel agents.

In an abstract to be presented at #SABCS26, the HER2 ADC IKS014 (caxmotabart entudotin) showed an ORR of 50% (5/10) among patients with HER2+ MBC that had previously received T-DXd.

https://t.co/MtXRmqYkQ5

[Kate Sears @OpenMedKate]

5/ @JaniceTNBCmets on remembering @AMJohnston1315 and telling your own story 🙏
https://t.co/FDNjxPDyCT

[Janice Cowden @JaniceTNBCmets]

Of course Abigail helped write her own obituary. Brutally honest, bittersweet & unapologetically HER. Even in death, she wasn’t about to let someone else tell her story. 💔

Two blog posts have appeared since her death. Every morning I hope there’s at least one more scheduled to drop in my inbox. ❤️‍🩹 #bcsm

https://t.co/5sTU5Oj0hw